Healthcare Stock Performance Analysis
Five Healthcare Firms Compared Across Revenue, Earnings, and Volatility Metrics
Anonymous
The comparisons produce mixed results: Vertex Pharmaceuticals is rated more favorably than Myriad Genetics, winning 12 of 15 categories, and is described as having higher revenue and earnings and lower volatility. Against Molecular Partners, Vertex also has higher revenue and earnings and lower volatility, but Molecular Partners is cheaper by price-to-earnings ratio and has the larger analyst-implied upside. vTv Therapeutics is favored over Enanta Pharmaceuticals based on its stronger analyst outlook, while Theravance Biopharma wins 9 of 15 comparison factors against vTv despite vTv’s higher analyst-implied upside. Septerna wins 10 of 15 factors against Valneva, although analysts see greater potential upside for Valneva.
Key Points
1
Vertex’s shares are much more institutionally held than Molecular Partners’: institutional investors own 91.0% of Vertex, compared with 26.6% of Molecular Partners. Insider ownership, however, is higher at Molecular Partners, at 5.9% versus 0.2% for Vertex.
2
In the vTv–Theravance comparison, institutional ownership is 99.1% for Theravance and 17.5% for vTv; their betas are 0.25 and 0.29, respectively, meaning both stocks are described as less volatile than the S&P 500.
3
Although vTv has higher earnings than Enanta, it has lower revenue; the article also reports institutional ownership of 95.0% for Enanta versus 17.5% for vTv.
4
Septerna has higher earnings but lower revenue than Valneva, and its stock is more volatile: its beta is 2.3, compared with Valneva’s 1.67.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
17
Articles
15
Reach
32
A
AnonymousAuthor
